Hospital Acquired Infections: Pseudomonas Aeruginosa

2430 Words5 Pages

Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative, rod-shaped aerobic bacterium. It is a primary cause of hospital-acquired infections. P. aeruginosa is primarily a nosocomial pathogen. It also acts as an opportunistic pathogen, which can only infect a host that is immunocompromised, due to an underlying disease or medication. Although, P. aeruginosa can cause damage to virtually any tissue in the body, it almost never affects the tissues of healthy individuals. It is a problematic pathogen in hospitals; infecting individuals with cancer, burn wound, catheters and cystic fibrosis. P. aeruginosa is most recognized for its resistance to a wide range of antibiotics. In its planktonic form, P. aeruginosa has been found to have many virulence factors. However, P. aeruginosa within biofilms have been found to have a resistance to antibiotics 1,000 times greater than that of its planktonic counterparts [4]. Infections that are caused by bacterial biofilms are very persistent and very difficult to treat.
Biofilms have been partially linked to the persistence of P. aeruginosa in Cystic fibrosis (CF) infections. In recent years, several methods of treatment have been developed, to prevent chronic P. aeruginosa biofilm infections. As a result of these methods, chronic P. aeruginosa infections that were once very common in CF children are rarely contracted in childhood and are more predominant in CF adults [5].

INTRODUCTION
P. aeruginosa is a nosocomial opportunistic pathogen that is highly resistant to antimicrobial agents. It is closely associated medical conditions such as periodontal disease, osteomyelitis and cystic fibrosis.
The resistance to many antibiotics is a well-known property of bacterial biofilms. Biofilms are dense...

... middle of paper ...

..., as chronic P. aeruginosa infections that were once prevalent in CF children, no longer infect most CF patients during childhood.

Treatment of chronic P. aeruginosa infections in CF lungs
Chronic suppressive antibiotic therapy is the recommended treatment of chronic P. aeruginosa infections in CF airways. This method of treatment consists of the daily use of nebulized tobramycin or colistin for the remainder of the patient’s life, along with a combination therapy consisting of two antibiotics, administered intravenously, every three months for two weeks[6]. Moreover, azithromycin as well as DNase are taken daily. Since chronic suppressive antibiotic therapy has proven to extend the life of CF patients and delay the weakening of pulmonary functions, some aspects of this therapy are steadily being used in biofilm infection treatment in other areas of the body.[6]

More about Hospital Acquired Infections: Pseudomonas Aeruginosa

Open Document